Navigation Links
Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference
Date:6/30/2011

POTOMAC, Md., June 30, 2011 /PRNewswire/ -- The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16th Annual Conference on June 26 in Maryland, US.  

With the theme of From Personal Genomes to Translational Medicine, the conference drew nearly 500 attendees with more than 30 distinguished speakers. Many sponsors supported and exhibited at the conference, including Chinese leading biotech parks, international pharmaceutical and biotech companies, US and Chinese government agencies, and international non-profit organizations.

Mr. Xiongfeng Chen, Counselor and Consul General of the Embassy of People's Republic of China in the USA, attended the conference. In his opening remarks, Mr. Chen recognized CBA’s contributions in promoting scientific communications and collaborations between the US and China, and encouraged the CBA to continue to serve as a bridge between the US and Chinese biopharmaceutical industries. He noted that China will spend $308 billion on science and technology by the end of 2015, and he believes the vast investment will further enhance scientific collaboration between the US and China.

During the conference, Zhifeng Long, PhD, CBA president (2011-2012), chairperson of the conference organizing committee, presented 2011 CBA Brilliant Achievement Award to Mr. Thomas Watkins, President and CEO, Human Genome Sciences Inc, and Jonathan M. Rothberg, PhD, Founder, CEO and Chairman, Ion Torrent Corporation, in recognition of their seminal contributions to science, technology or business development in the biopharmaceutical fields, and their efforts in promoting public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

Dr Long also presented the 2011 CBA Outstanding Public Service Award to Yuling Li, PhD, former CBA president (2007-2008), Fellow at Bioprocess Chemistry, MedImmune, in appreciation of her long-term contribution to the growth of the CBA, her dedication in promoting CBA members’ career advancement, and her long-lasting efforts in carrying out CBA’s mission of facilitating collaboration between biopharmaceutical professionals and promoting global business collaboration in biopharmaceutical fields.

CBA also held its annual election for president-elect during the conference. Richard Y. Zhao, PhD, professor of pathology, Microbiology-Immunology and Human Virology, University of Maryland School of Medicine, was elected CBA’s new president-elect (2011-2012). According to CBA’s bylaws, Dr Zhifeng Long becomes CBA’s president (2011-2012) and Dr Sujuan Ba becomes CBA’s immediate-past president after the annual conference.

In his inaugural speech, Dr Zhao promised to honor CBA’s tradition, to attract new blood from old and young, to maximize each CBA member’s potential, and to promote in-depth collaboration with biopharmaceutical partners to achieve a greater impact of CBA worldwide.

In his closing remarks, Dr Long expressed his sincere appreciation for the strong support and broad participation of CBA members and friends and for the generous support from the speakers and sponsors, many of which exhibited and showcased their products during the conference. 

About the Chinese Biopharmaceutical Association - USAThe Chinese Biopharmaceutical Association – USA (CBA) is one of the largest Chinese American professional associations in the United States.  Founded in 1995, CBA is an independent, non-political, not for-profit professional organization dedicated to promoting science, technology, and business development in the biopharmaceutical fields by fostering research and business collaborations around the world.  The Association is led by its elected board of directors and executive committee.  For more information about the CBA and its programs, visit www.cba-usa.org. News contact:

Sabrina XuVice President for CommunicationsChinese Biopharmaceutical Association-USAcontact@cba-usa.org
'/>"/>

SOURCE Chinese Biopharmaceutical Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
2. Nolan Law Group: Jury Finds Against Baxter Healthcare In Nations First Contaminated Chinese Heparin Case
3. University of Pennsylvania Announces Partnership with Chinese Academy of Sciences for Center of Excellence in Brain Mapping
4. Reportlinker Adds Chinese Pharmaceutical Regulatory Report 2011
5. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
6. Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE
7. Visual Healthcare to Support Chinese Clinical Trials
8. Tongjitang Chinese Medicines Company Shareholders Vote to Approve Merger
9. Newtech, Inc., a Leading Chinese EMS Patient Monitoring Company, Partners With Masimo to Incorporate rainbow® SET Noninvasive Measurement Capabilities Into New Patient Monitors
10. Chinese Army Established the First Chest Pain Rescue Network in China by Using IVT mHealth System
11. Tongjitang Chinese Medicines Company Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):